Corvus Pharmaceuticals
CRVS
124 hedge funds and large institutions have $359M invested in Corvus Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 29 reducing their positions, and 7 closing their positions.
329% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 7
41% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 29
22% more funds holding
Funds holding: 102 → 124 (+22)
17% more capital invested
Capital invested by funds: $307M → $359M (+$52.4M)
6.58% more ownership
Funds ownership: 55.93% → 62.51% (+6.6%)
8% less call options, than puts
Call options by funds: $4.76M | Put options by funds: $5.15M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$23.3M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$21.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.1M |
| 4 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$5.75M |
| 5 |
Millennium Management
New York
|
+$5.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28.2M |
| 2 |
RI
RTW Investments
New York
|
-$17.6M |
| 3 |
PA
Perceptive Advisors
New York
|
-$5.88M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$3.05M |
| 5 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
-$2.76M |
CRVS Hedge Fund Activity: Q4 2025 in Review
124 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2025, worth a combined $359M — up 17% from $307M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CRVS positions and 7 closed out — a net gain of 23 holders — while 41 added to existing stakes and 29 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $23.3M. The largest seller was Point72 Asset Management, cutting an estimated $28.2M.
- 124 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2025, up from 102 in Q3 2025.
- Funds reported $359M of Corvus Pharmaceuticals stock for Q4 2025, up 17% quarter-over-quarter.
- 30 funds opened new Corvus Pharmaceuticals positions in Q4 2025 and 7 closed out, a net change of +23 holders.
- The largest Corvus Pharmaceuticals buyer in Q4 2025 was Morgan Stanley, an estimated $23.3M added.
- The largest Corvus Pharmaceuticals seller in Q4 2025 was Point72 Asset Management, an estimated $28.2M sold.
Based on aggregated 13F filings for Q4 2025.